Crispr Therapeut Stock Price, News & Analysis

CRISPR Therapeutics presented data from their Phase 1/2 clinical trial of CTX112™, a next-generation CD19 allogeneic CAR T cell therapy, showing promising results in treating relapsed or refractory B-cell malignancies. The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX112 for treating R/R follicular lymphoma and marginal zone lymphoma.

Key findings include:

• 67% objective response rate across all dose levels
• 50% complete response rate
• Well-tolerated safety profile with no Grade ≥3 infections
• Five patients achieved responses lasting over 6 months

The trial involved 12 subjects treated with varying doses, demonstrating dose-dependent efficacy. CTX112 is also being tested in a Phase 1 trial for systemic lupus erythematosus, with potential expansion into other autoimmune indications. A broader update across indications is expected in mid-2025.

CRISPR Therapeutics (Nasdaq: CRSP) has announced its participation in the upcoming Jefferies London Healthcare Conference. CEO and Chairman Samarth Kulkarni, Ph.D., will deliver a presentation on Wednesday, November 20, 2024, at 4:00 p.m. GMT. The presentation will be accessible through a live webcast on the company's website under the 'Events & Presentations' section, with a replay available for 14 days afterward. CRISPR Therapeutics specializes in developing transformative gene-based medicines for serious diseases.

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company specializing in gene-based medicines, has announced that their CEO and Chairman, Samarth Kulkarni, Ph.D., will present at the Guggenheim Inaugural Healthcare Innovation Conference. The presentation is scheduled for Tuesday, November 12, 2024, at 2:00 p.m. ET.

A live webcast of the fireside chat will be accessible through the company's website's 'Events & Presentations' page in the Investors section. The webcast recording will remain available for 14 days after the presentation.

CRISPR Therapeutics reported Q3 2024 financial results and business updates. Key highlights include regulatory approvals for CASGEVY in Switzerland and Canada for treating sickle cell disease and transfusion-dependent beta thalassemia in patients 12 and older. The company has activated 45 authorized treatment centers globally, with approximately 40 patients having cells collected. Financial results show a strong balance sheet with $1.9 billion in cash and equivalents. Q3 net loss was $85.9 million, improved from $112.2 million in Q3 2023. R&D expenses decreased to $82.2 million from $90.7 million year-over-year. The company is advancing multiple clinical trials including CTX112 and CTX131 for various indications.

CRISPR Therapeutics (Nasdaq: CRSP) reported its Q2 2024 financial results, highlighting progress across its pipeline. Key points include:

1. CASGEVY launch momentum with over 35 authorized treatment centers activated globally and approximately 20 patients with cells collected.

2. Advancement of next-generation CAR T programs CTX112 and CTX131 in multiple indications.

3. Ongoing clinical trials for in vivo gene editing candidates CTX310 and CTX320.

4. Strong financial position with $2 billion in cash and equivalents as of June 30, 2024.

5. Q2 2024 net loss of $126.4 million, compared to $77.7 million in Q2 2023.

6. R&D expenses decreased to $80.2 million from $101.6 million year-over-year.

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on gene-based medicines for serious diseases, announced its participation in upcoming investor conferences. Their senior management team will present at the Jefferies Healthcare Conference on June 5, 2024, at 10:00 a.m. ET, and the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024, at 9:20 a.m. ET. Live webcasts of these presentations will be accessible on the Investor section of the company's website and archived for 14 days post-event.

CRISPR Therapeutics (Nasdaq: CRSP) has announced key executive appointments. Dr. Naimish Patel will join as Chief Medical Officer effective May 28, 2024. Dr. Patel brings extensive experience from Sanofi, where he led the Global Development Therapeutic Area of Immunology and Inflammation. Additionally, Julianne Bruno has been promoted to Chief Operating Officer effective May 23, 2024. Ms. Bruno has been with CRISPR Therapeutics since 2019 and played a important role in the partnership with Vertex. These leadership changes aim to bolster CRISPR Therapeutics' capabilities in advancing its portfolio of gene-based medicines for serious diseases.

CRISPR Therapeutics will be presenting at the Bank of America Securities Health Care Conference on May 15, 2024. The company's senior management team will discuss their transformative gene-based medicines for serious diseases. The event will be live webcasted and available for replay on the company's website.

CRISPR Therapeutics reported strong financial results for the first quarter of 2024, with a focus on expanding its pipeline and advancing clinical trials. The company has over 25 authorized treatment centers globally for CASGEVY™ and has activated multiple clinical trials for next generation CAR T and in vivo gene editing products. CRISPR Therapeutics also expanded its pipeline with new preclinical programs targeting refractory hypertension and acute hepatic porphyria. The company reported a strong balance sheet with approximately $2.1 billion in cash, cash equivalents, and marketable securities as of March 31, 2024.